No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
TSHA250117P5000
- 2.65
- 0.000.00%
15min DelayClose Jan 10 16:00 ET
0.00High0.00Low
2.65Open2.65Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover565.79%IV-33.52%PremiumJan 17, 2025Expiry Date3.24Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8337Delta0.1848Gamma0.53Leverage Ratio-0.0238Theta-0.0007Rho-0.44Eff Leverage0.0006Vega
Intraday
- 5D
- Daily
News
Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $6
Taysha Gene Therapies: Promising Developments and Strategic Investment Opportunity
Express News | Taysha Gene Therapies Files for Mixed Shelf Offering of up to $300 Mln - SEC Filing
Express News | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
JMP Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5
Buy Rating for Taysha Gene Therapies Due to Safer Administration Method and Lower Viral Dose